| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/04/2006 | CN1234414C Drugs for complications of diabetes and neuropathy and utilization thereof |
| 01/04/2006 | CN1234413C Synergistic composition and its use |
| 01/04/2006 | CN1234371C Application of nano copper powder for preparing medicine for prophylaxis of osteoporosis and bone fracture |
| 01/04/2006 | CN1234366C Use of active vitamin D analogue in preparing medicine for treating hyperproliferative diseases |
| 01/04/2006 | CN1234362C Opioid agonist/antagonist combinations |
| 01/04/2006 | CN1234357C Antihypersensitive combination of valsartan and calcium channel blocker |
| 01/04/2006 | CN1234352C Treatment of PCP addiction and PCP addiction-related behavior |
| 01/04/2006 | CN1234344C Inhalation composition |
| 01/03/2006 | US6982353 C2-disubstituted indan-1-ol compounds, their derivatives, processes for their preparation, and their use as pharmaceuticals |
| 01/03/2006 | US6982320 Cytokine receptor common gamma chain like |
| 01/03/2006 | US6982279 Arylated furan- and thiophenecarboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| 01/03/2006 | US6982277 Antitumor agents, antiinflammatory agents; for example 2-(2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-yl)-1-(4-methylphenyl) -1-ethanone, 2-(4-methylphenyl)-5,6,7,8-tetrahydrobenzo(d)-imidazo(2,1-b)thiazole |
| 01/03/2006 | US6982270 1-Phenyl-2-oxo-3,4-dihydro-6-phenylaminoquinazoline for example; cytokine suppressive anti-inflammatory drugs; combination therapy |
| 01/03/2006 | US6982268 Useful in the treatment of a variety of central nervous system disorders in humans including anxiety, depression, sleep disorders, attention deficit disorder, or Alzheimer's dementia |
| 01/03/2006 | US6982267 For therapy of metabolic and eating disorders such as obesity and hyperphagia, and therapy of diabetes |
| 01/03/2006 | US6982262 Combination of cyamemazine and an atypical neuroleptic |
| 01/03/2006 | US6982258 Low-calcemic oxime analogs of 1α,25-dihydroxy vitamin D3 |
| 01/03/2006 | US6982255 Comprises coadministration of galactomannan and chemotherapeutic agent (adriamycin) |
| 01/03/2006 | US6982253 Liquid formulation of decitabine and use of the same |
| 01/03/2006 | US6982251 As cholesterol-lowering agent and a cholesterol biosynthesis inhibitor for therapy and prophylaxis of atherosclerosis |
| 01/03/2006 | US6982248 Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| 01/03/2006 | US6982157 Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4 |
| 01/03/2006 | US6982099 Composition and method for smoke detoxification |
| 01/03/2006 | CA2329005C Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/03/2006 | CA2264901C Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 01/03/2006 | CA2162586C Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
| 12/29/2005 | WO2005123907A2 Ex-vivo application of solid microparticulate therapeutic agents |
| 12/29/2005 | WO2005123193A2 Treatments comprising strontium for rheumatic and arthritic diseases and pain |
| 12/29/2005 | WO2005123132A2 Use of liver-selective glucokinase activators |
| 12/29/2005 | WO2005123131A2 High pressure spray-dry of bioactive materials |
| 12/29/2005 | WO2005123130A2 Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor |
| 12/29/2005 | WO2005123109A2 Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use |
| 12/29/2005 | WO2005123098A2 Preventing gastrointestinal side-effects with strontium salts |
| 12/29/2005 | WO2005123097A1 Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder |
| 12/29/2005 | WO2005123093A2 Ophthalmic formulations including selective alpha 1 antagonists |
| 12/29/2005 | WO2005123076A2 Pharmaceutical compositions |
| 12/29/2005 | WO2005123072A1 Methods and compositions for the treatment of pulmonary diseases |
| 12/29/2005 | WO2005123071A1 Methods of using albuterol and calcium activated potassium channel openers |
| 12/29/2005 | WO2005123069A2 Gram-positive carbapenem antibacterials and processes for their preparation |
| 12/29/2005 | WO2005123068A2 Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
| 12/29/2005 | WO2005123066A1 Carbapenem antibacterials with gram-negative activity and processes for their preparation |
| 12/29/2005 | WO2005123064A1 Adrenergic complement inhaler comprising compounds such as ascorbates tocopherols or polycaboxylic acid chelators |
| 12/29/2005 | WO2005123061A1 Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent |
| 12/29/2005 | WO2005123055A2 Methods for treating inflammatory disorders |
| 12/29/2005 | WO2005091872A3 Pharmaceutical composition and method for the transdermal delivery of magnesium |
| 12/29/2005 | WO2005072343A3 Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use |
| 12/29/2005 | WO2005065121A3 Methods and compositions for the production of monoclonal antibodies |
| 12/29/2005 | WO2005058244A3 Novel anti-dc-sign antibodies |
| 12/29/2005 | WO2005053661A3 Pharmaceutical combinations |
| 12/29/2005 | WO2005049088A3 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent |
| 12/29/2005 | WO2005032480A3 Methods, compositions,, apparatuses containing tetrameric oxygen |
| 12/29/2005 | WO2004094599A3 Disease prevention and vaccination following thymic reactivation |
| 12/29/2005 | WO2004092122A3 Preparation and purification of synthetic capsaicin |
| 12/29/2005 | WO2004082636A3 Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor |
| 12/29/2005 | WO2004082631A3 METHODS FOR PREPARATION AND USE OF 1α,24(S)-DIHYDROXYVITAMIN D2 |
| 12/29/2005 | WO2004069166A3 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 12/29/2005 | WO2004034965A3 Method for treating cancer |
| 12/29/2005 | WO2004004661A3 Boroproline compound combination therapy |
| 12/29/2005 | WO2003071933A3 Novel compositions and methods for cancer |
| 12/29/2005 | WO2003033671A3 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 12/29/2005 | WO2003012122A3 Crystallized structure of type iv collagen nc1 domain hexamer |
| 12/29/2005 | WO2002099040A3 Igs as modifiers of the p53 pathway and methods of use |
| 12/29/2005 | US20050289660 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 12/29/2005 | US20050289657 Diagnostic and therapeutic use of an atp-binding cassette gene and protein for neurodegenerative diseases |
| 12/29/2005 | US20050288487 Human mast cell-expressed membrane proteins |
| 12/29/2005 | US20050288375 Method and composition for treating neurodegenerative disorders |
| 12/29/2005 | US20050288368 Compositions and methods for treating and preventing necrosis |
| 12/29/2005 | US20050288359 Agents and methods for the treatment of disorders associated with oxidative stress |
| 12/29/2005 | US20050288355 Combination therapy wherein a serotonin reuptake inhibitor is used |
| 12/29/2005 | US20050288339 Medicinal compositions containing diuretic and insulin resistance-improving agent |
| 12/29/2005 | US20050288325 Therapy for andropause using estrogen agonists/antagonists and testosterone |
| 12/29/2005 | US20050288323 Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine |
| 12/29/2005 | US20050288313 Synergistically combined with immunomodulators or antiinflammtory agents; treating rheumatoid arthritis; inhibiting organ transplant rejection; Janus Kinase 3 inhibitors such as CP 690550, 3-{4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile |
| 12/29/2005 | US20050288303 Cyclic protein tyrosine kinase inhibitors |
| 12/29/2005 | US20050288299 Preferably p38-alpha; azaindoles, azabenzofurans, or azabenzothiophenes are coupled through a piperidine or piperazine type linker to another cyclic moiety; antiarthritic, anticarcinogenic, antiinflammatory agents; analgesics |
| 12/29/2005 | US20050288294 N-ethyl-N'-{(3R)-1-[4-(3-phenylthieno[3,4-b]pyrazin-2-yl)benzyl]pyrrolidin-3-yl}urea; inhibit activity of a serine, threonine protein kinase; cancer |
| 12/29/2005 | US20050288291 Modulation of cell fates and activities by phthalazinediones |
| 12/29/2005 | US20050288266 Combinations comprising antimuscarinic agents and corticosteroids |
| 12/29/2005 | US20050288265 Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allegic diseases, asthma and copd |
| 12/29/2005 | US20050288254 Treating sepsis or septic shock by administering 1-stearoyl, 1-palmitoyl-, 1-myristoyl- lysophosphatidylcholine, or 1-oleoyllysophosphatidylcholine or sphingosylphosphorylcholine. |
| 12/29/2005 | US20050288249 Testing a compound for the ability to inhibit PKG I alpha; testing the compound for the ability to inhibit PKG I beta; identifying the compound as a candidate drug useful in the treatment of pain ifit selectively inhibits PKG I alpha relative to PKG I beta . |
| 12/29/2005 | US20050288230 Non-steroidal anti-androgen therapy |
| 12/29/2005 | US20050288222 Methods for enhancing the bioavailability of a drug |
| 12/29/2005 | US20050288215 Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| 12/29/2005 | US20050288213 Combination therapy for the treatment of obesity |
| 12/29/2005 | US20050287617 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 12/29/2005 | US20050287546 Novel proteases |
| 12/29/2005 | US20050287529 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof |
| 12/29/2005 | US20050287232 Skin immune function controlling agents |
| 12/29/2005 | US20050287230 Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof |
| 12/29/2005 | US20050287207 Solid preparation |
| 12/29/2005 | US20050287206 Solubilized CoQ-10 and carnitine |
| 12/29/2005 | US20050287204 Nutritional or pharmaceutical compositions for increasing the creatine response of organisms |
| 12/29/2005 | US20050287199 Therapeutic micro nutrient composition for lipolysis and drug delivery |
| 12/29/2005 | US20050287189 Antitumor, anticancer agents; particles or coils or stents coated solid-phase agent comprising a binding agent comprising collagen are directed to target vasculature, such as the vasculature of solid tumor masses or aneurysms |
| 12/29/2005 | US20050287182 Cosmetic or dermatological preparation comprising a nutrient medium phase |
| 12/29/2005 | US20050287180 Phospholipid compositions and methods for their preparation and use |
| 12/29/2005 | US20050287145 Compositions and methods for producing vascular occlusion |
| 12/29/2005 | US20050287144 For the modulation of signal activities controlled by NF-kappa B-inducing kinase (NIK); cancer , rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, cardiac infarct, Alzheimer's disease, or atherosclerosis |
| 12/29/2005 | US20050287139 Wound healing |